Evaluating outcomes of mother-infant pairs using dolutegravir for HIV treatment during pregnancy

Evaluating outcomes of mother-infant pairs using dolutegravir for HIV treatment during pregnancy

Dolutegravir (DTG), a second-generation integrase inhibitor, is an effective treatment for HIV but its safety and efficacy are not well established in pregnancy. Here, we assess maternal and infant outcomes of mother-infant pairs using DTG-containing regimens during pregnancy. We performed a retrosp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:AIDS (London) 2018-09, Vol.32 (14), p.2017-2021
Hauptverfasser: Grayhack, Clara, Sheth, Anandi, Kirby, Olivia, Davis, Jennifer, Sibliss, Kedesha, Nkwihoreze, Hervette, Aaron, Erika, Alleyne, Gregg, Laguerre, Roberta, Rana, Aadia, Badell, Martina, Momplaisir, Florence
Format: Artikel
Sprache:eng
Schlagworte:
AIDS/HIV
Clinical Science: Concise Communication
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Dolutegravir (DTG), a second-generation integrase inhibitor, is an effective treatment for HIV but its safety and efficacy are not well established in pregnancy. Here, we assess maternal and infant outcomes of mother-infant pairs using DTG-containing regimens during pregnancy. We performed a retrospective cohort analysis of pregnant women with HIV on DTG from two urban clinics in the United States, 2015-2018. Maternal outcomes included viral suppression (viral load of
ISSN:0269-9370
1473-5571
DOI:10.1097/QAD.0000000000001931